Belgian immunology and inflammatory biotech AgomAb Therapeutics files for a $100 million US IPO
February 6, 2026 News
Belgian fibrotic disease biotech AgomAb Therapeutics prices IPO at $16 midpoint, raising $200 million
AgomAb Therapeutics, a Belgian Phase 2 biotech developing novel therapies for chronic fibrotic disorders, raised $200 million by offering 12.5 million ADSs at $16, the midpoint of the range of $15 to $17.
January 29, 2026 News
Belgian fibrotic disease biotech AgomAb Therapeutics sets terms for $200 million US IPO
AgomAb Therapeutics, a Belgian Phase 2 biotech developing TGFβ inhibitors for Crohn’s and other fibrotic diseases, announced terms for its IPO on Thursday.
The Antwerp, Belgium-based company plans to raise $200 million by offering 12.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, AgomAb Therapeutics would command a fully diluted market value of $875 million.
IPO Overview
AgomAb Therapeutics, a Belgium-based Phase 2 biotech focused on immunology and inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. The company’s initial focus is on chronic fibrotic indications with high unmet medical need, through inhibition of one of the key signaling pathways involved in fibrosis, the transforming growth factor ?, or TGF?, pathway. AgomAb Therapeutics’ lead product candidate, ontunisertib （AGMB-129）， is a selective and potent oral, gastrointestinal-restricted small molecule inhibitor of ALK5, or TGF?R1, in development for the treatment of Fibrostenosing Crohn’s Disease, or FSCD. AGMB-447, its second clinical-stage product candidate, is an inhaled small molecule inhibitor of ALK5, or TGF?R1, in development for the treatment of idiopathic pulmonary fibrosis, or IPF.
The Antwerp, Belgium-based company was founded in 2017 and plans to list on the Nasdaq under the symbol AGMB. AgomAb Therapeutics filed confidentially on June 20, 2024. J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are the joint bookrunners on the deal. No pricing terms were disclosed.
About the Company
We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. /Our initial focus for the treatment of fibrosis is through inhibition of one of the key signaling pathways involved in fibrosis, the transforming growth factor ?, or TGF?, pathway. /Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives. Our lead product candidate, ontunisertib （AGMB-129）， is a selective and potent oral, gastrointestinal-restricted small molecule inhibitor of ALK5, or TGF?R1, in development for the treatment of Fibrostenosing Crohn’s Disease, or FSCD. FSCD is a severe complication of Crohn’s Disease, or CD, that is associated with significant morbidity. AGMB-447, our second clinical-stage product candidate, is an inhaled small molecule inhibitor of ALK5, or TGF?R1, in development for the treatment of idiopathic pulmonary fibrosis, or IPF. We have a robust discovery pipeline including several programs in the early stages of development.